Five Prime Therapeutics Company Profile (NASDAQ:FPRX)

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: FPRX
CUSIP:

Key Metrics:

Previous Close: $51.84
50 Day Moving Average: $48.45
200 Day Moving Average: $44.85
52-Week Range: $15.00 - $55.00
Trailing P/E Ratio: 5.90
Foreward P/E Ratio: -15.04
P/E Growth: 0.78
Market Cap: $1.41B
Outstanding Shares: 26,923,000
Beta: 4.51

Profitability:

Net Margins: 63.88%
Return on Equity: 69.59%
Return on Assets: 56.21%

Debt:

Current Ratio: 10.88%
Quick Ratio: 10.88%

Additional Links:

Companies Related to Five Prime Therapeutics:

Consensus Ratings for Five Prime Therapeutics (NASDAQ:FPRX) (?)

Ratings Breakdown:	1 Hold Rating, 5 Buy Ratings
Consensus Rating:	Buy (Score: 2.83)
Consensus Price Target:	$53.60 (2.11% upside)

Analysts' Ratings History for Five Prime Therapeutics (NASDAQ:FPRX)

Show:

Date	Firm	Action	Rating	Price Target
8/8/2016	Leerink Swann	Reiterated Rating	Outperform	$45.00 -> $58.00
8/5/2016	Jefferies Group	Set Price Target	Buy	$41.00 -> $60.00
7/12/2016	Credit Suisse Group AG	Reiterated Rating	Buy
5/19/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Outperform	$48.00
4/12/2016	BMO Capital Markets	Initiated Coverage	Market Perform	$50.00
12/4/2015	Wells Fargo & Co.	Reiterated Rating	Outperform
7/31/2015	Citigroup Inc.	Initiated Coverage	Neutral -> Buy	$33.00
5/13/2015	Guggenheim	Initiated Coverage	Buy	$31.00

(Data available from 10/1/2014 forward)

Earnings History for Five Prime Therapeutics (NASDAQ:FPRX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/2/2016
8/4/2016	Q2	($0.56)	($0.49)	$6.38 million	$9.23 million	View	N/A
5/5/2016	Q1	($0.71)	($0.49)	$5.26 million	$6.50 million	View	N/A
3/10/2016	Q4	$9.67	$10.63	$354.16 million	$363.34 million	View	Listen
11/4/2015	Q315	($0.99)	($0.93)	$4.90 million	$5.90 million	View	N/A
8/6/2015	Q215	($0.44)	($0.45)	$6.92 million	$6.30 million	View	N/A
5/13/2015	Q1	($0.53)	($0.44)	$4.77 million	$4.30 million	View	Listen
3/17/2015	Q414	($0.10)	($0.55)		$4.65 million	View	N/A
11/10/2014		($0.40)	($0.33)			View	N/A
8/5/2014	Q2 14	($0.27)	($0.46)			View	N/A
3/25/2014	Q4	($0.40)	($0.43)			View	Listen
11/12/2013		($0.57)	($2.74)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-3.49 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	3	($0.87)	($0.46)	($0.62)
Q2 2016	2	($0.76)	($0.57)	($0.67)
Q3 2016	3	($0.80)	($0.53)	($0.65)
Q4 2016	3	($1.38)	($0.59)	($0.88)

(Data provided by Zacks Investment Research)

Dividend History for Five Prime Therapeutics (NASDAQ:FPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Five Prime Therapeutics (NASDAQ:FPRX)

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 86.49%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/1/2016	William R Ringo	Director	Sell	500	$44.20	$22,100.00
8/1/2016	William R Ringo	Director	Sell	500	$50.77	$25,385.00
7/27/2016	Peder Jensen	Director	Sell	12,195	$49.50	$603,652.50
4/22/2016	Franklin M Berger	Director	Buy	5,000	$49.47	$247,350.00
4/22/2016	Marc Belsky	CFO	Sell	34,102	$50.00	$1,705,100.00
4/21/2016	Lewis T Williams	CEO	Sell	48,671	$48.05	$2,338,641.55
4/19/2016	Franklin M Berger	Director	Buy	6,090	$47.06	$286,595.40
4/15/2016	Lewis T Williams	CEO	Sell	1,405	$48.00	$67,440.00
4/14/2016	Lewis T Williams	CEO	Sell	2,725	$48.00	$130,800.00
4/6/2016	Lewis T Williams	CEO	Sell	52,801	$43.09	$2,275,195.09
4/6/2016	Marc Belsky	CFO	Sell	20,814	$45.04	$937,462.56
3/30/2016	Francis Willard Sarena	EVP	Sell	10,000	$40.01	$400,100.00
3/30/2016	Lewis T Williams	CEO	Sell	23,259	$40.02	$930,825.18
3/30/2016	Marc Belsky	CFO	Sell	13,876	$40.01	$555,178.76
3/2/2016	Lewis T Williams	CEO	Sell	23,259	$36.01	$837,556.59
2/4/2016	Lewis T. Williams	CEO	Sell	71,229	$33.35	$2,375,487.15
1/27/2016	Francis Willard Sarena	EVP	Sell	30,000	$35.22	$1,056,600.00
10/15/2015	Adage Capital Partners Gp Llc	Major Shareholder	Sell	125,000	$27.75	$3,468,750.00
10/15/2015	Lewis T. Williams	CEO	Sell	72,352	$27.24	$1,970,868.48
9/21/2015	Lewis T Williams	CEO	Sell	2,648	$22.06	$58,414.88
6/22/2015	Lewis T Williams	CEO	Sell	75,000	$24.67	$1,850,250.00
1/28/2015	Franklin M Berger	Director	Buy	25,000	$27.03	$675,750.00
1/15/2015	Franklin M Berger	Director	Buy	10,049	$26.17	$262,982.33
11/28/2014	Franklin M Berger	Director	Buy	1,951	$21.04	$41,049.04
11/4/2014	Lewis T Williams	CEO	Sell	32,603	$13.08	$426,447.24
10/30/2014	Lewis T Williams	CEO	Sell	17,397	$13.13	$228,422.61
9/23/2013	Brian G Atwood	Director	Buy	76,923	$13.00	$999,999.00

(Data available from 1/1/2013 forward)

Latest Headlines for Five Prime Therapeutics (NASDAQ:FPRX)

Date	Headline
	Analyst Coverage: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - NewsDen (NASDAQ:FPRX) newsden.net - October 1 at 10:29 AM
	Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Updated Broker Price Targets - The De Soto Edge (NASDAQ:FPRX) desotoedge.com - September 29 at 10:06 AM
	Notable Technical Move: Five Prime Therapeutics Inc Forms Bullish Wedge Up Pattern; Strong Momentum for Buyers ... - Chester News (NASDAQ:FPRX) www.chesterindependent.com - September 28 at 4:56 PM
	Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease Immuno-Oncology Roundtable - EconoTimes (NASDAQ:FPRX) www.econotimes.com - September 24 at 4:48 PM
	Five Prime Therapeutics to Present at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable (NASDAQ:FPRX) www.publicnow.com - September 22 at 5:08 PM
	4:42 pm Five Prime Therapeutics promotes Aron Knickerbocker to Chief Operating Officer, Francis Sarena to Chief Strategy Officer and Luis Borges, Ph.D., to Senior Vice President, Resea (NASDAQ:FPRX) finance.yahoo.com - September 21 at 9:19 AM
	Five Prime Therapeutics Announces Key Executive Promotions (NASDAQ:FPRX) www.publicnow.com - September 21 at 9:19 AM
	BRIEF-Five Prime Therapeutics says Aron Knickerbocker promoted to COO (NASDAQ:FPRX) feeds.reuters.com - September 20 at 5:19 PM
	Stock Pattern: How Analysts Feel About Five Prime Therapeutics Inc After Forming Wedge Up Chart Pattern? - Chester News (NASDAQ:FPRX) www.chesterindependent.com - September 18 at 9:41 AM
	Five Prime Therapeutics (Nasdaq: FPRX) to Ring The Nasdaq Stock Market Opening Bell - GlobeNewswire (press release) (NASDAQ:FPRX) globenewswire.com - September 17 at 4:54 PM
	Five Prime Therapeutics (Nasdaq: FPRX) to Ring The Nasdaq Stock Market Opening Bell (NASDAQ:FPRX) www.publicnow.com - September 16 at 4:58 PM
	What's Next for Five Prime Therapeutics Inc After Today's Huge ... - Chester News (NASDAQ:FPRX) www.chesterindependent.com - September 15 at 8:07 AM
	FIVE PRIME THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:FPRX) www.4-traders.com - September 14 at 5:09 PM
	FIVE PRIME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:FPRX) biz.yahoo.com - September 14 at 5:09 PM
	Can Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $60 - Investor Newswire (NASDAQ:FPRX) www.investornewswire.com - September 12 at 4:56 PM
	Telemetry Investments L.l.c. Lowers stake in Five Prime Therapeutics Inc (FPRX) - National Daily Press (NASDAQ:FPRX) www.nationaldailypress.com - September 10 at 4:45 PM
	Telemetry Investments L.l.c. Lowers stake in Five Prime Therapeutics Inc (FPRX) (NASDAQ:FPRX) www.nationaldailypress.com - September 10 at 9:39 AM
	Five Prime Therapeutics, Inc. – Value Analysis (NASDAQ:FPRX) : September 9, 2016 (NASDAQ:FPRX) www.capitalcube.com - September 9 at 4:56 PM
	Stock Showing Gains in Today's Session: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) - Post News (NASDAQ:FPRX) www.kentuckypostnews.com - September 8 at 4:59 PM
	Placing Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares Under the Microscope - Post News (NASDAQ:FPRX) www.kentuckypostnews.com - September 8 at 8:57 AM
	Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FPRX-US : September 8, 2016 (NASDAQ:FPRX) www.capitalcube.com - September 8 at 8:57 AM
	Five Prime Therapeutics to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:FPRX) www.publicnow.com - September 6 at 5:01 PM
	Stock in Review: Taking a Closer Look at Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Shares - Post News (NASDAQ:FPRX) www.kentuckypostnews.com - September 1 at 5:29 AM
	Why Do Hedge Funds Like Five Prime Therapeutics? - Insider Monkey (blog) (NASDAQ:FPRX) www.insidermonkey.com - August 31 at 5:37 PM
	Why Do Hedge Funds Like Five Prime Therapeutics? (NASDAQ:FPRX) feedproxy.google.com - August 31 at 12:54 PM
	Can Shares Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Get To $60? - Investor Newswire (NASDAQ:FPRX) www.investornewswire.com - August 29 at 5:01 PM
	Five Prime Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FPRX-US : August 25, 2016 (NASDAQ:FPRX) www.capitalcube.com - August 25 at 10:04 AM
	ETF’s with exposure to Five Prime Therapeutics, Inc. : August 23, 2016 (NASDAQ:FPRX) www.capitalcube.com - August 23 at 5:12 PM
	Will Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Hit $60 Price Target? - Investor Newswire (NASDAQ:FPRX) www.investornewswire.com - August 15 at 5:14 PM
	Five Prime Therapeutics, Inc. (FPRX) Ownership Increased by Fmr ... - Finance Daily (NASDAQ:FPRX) www.fidaily.com - August 12 at 8:03 AM
	ETF’s with exposure to Five Prime Therapeutics, Inc. : August 11, 2016 (NASDAQ:FPRX) www.capitalcube.com - August 11 at 5:17 PM
	FIVE PRIME THERAPEUTICS INC Financials (NASDAQ:FPRX) finance.yahoo.com - August 11 at 5:17 PM
	Five Prime Therapeutics Could Be The Ace Up The Sleeve Of Bristol-Myers Squibb (NASDAQ:FPRX) seekingalpha.com - August 9 at 9:26 PM
	Monday's ETF Movers: XOP, XBI (NASDAQ:FPRX) www.forbes.com - August 9 at 3:49 PM
	Five Prime Therapeutics, Inc. :FPRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 (NASDAQ:FPRX) www.capitalcube.com - August 9 at 3:49 PM
	Analysts Spotlight: Five Prime Therapeutics, Inc. (NASDAQ:FPRX) , Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Street Updates (NASDAQ:FPRX) www.streetupdates.com - August 9 at 8:01 AM
	Monday's Market Wrap: Stocks Begin Week With Minor Losses (NASDAQ:FPRX) feeds.benzinga.com - August 8 at 7:03 PM
	Worth Watching Stocks to Track: Five Prime Therapeutics Inc (NASDAQ:FPRX), US Foods Holding Corp (NYSE:USFD) - NYSE Journal (press release) (NASDAQ:FPRX) stockznews.com - August 6 at 5:23 PM
	Five Prime Therapeutics Inc. 2Q earnings released (NASDAQ: FPRX) - BNB Daily (blog) (NASDAQ:FPRX) www.baseball-news-blog.com - August 5 at 5:10 PM
	FIVE PRIME THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:FPRX) biz.yahoo.com - August 5 at 5:09 PM
	Edited Transcript of FPRX earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:FPRX) finance.yahoo.com - August 5 at 5:09 PM
	Five Prime Therapeutics Inc. (FPRX) is Trading Lower on Unusual Volume for August 02 - Equities.com (NASDAQ:FPRX) www.equities.com - August 5 at 5:28 AM
	Five Prime Therapeutics Inc. (FPRX) is Trading Higher on Unusual ... - Equities.com (NASDAQ:FPRX) www.equities.com - August 5 at 5:28 AM
	Five Prime Therapeutics posts 2Q loss - Yahoo Finance (NASDAQ:FPRX) finance.yahoo.com - August 4 at 10:50 PM
	Five Prime Therapeutics posts 2Q loss (NASDAQ:FPRX) sg.finance.yahoo.com - August 4 at 10:50 PM
	Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma (NASDAQ:FPRX) www.prnewswire.com - August 4 at 5:24 PM
	Five Prime Therapeutics Inc.: Five Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX) www.twst.com - August 4 at 5:24 PM
	Five Prime Announces Second Quarter 2016 Results and Provides Business Update (NASDAQ:FPRX) www.publicnow.com - August 4 at 5:24 PM
	Five Prime Therapeutics Inc. (FPRX) Hits New 52-week High During August 01 Session - Equities.com (NASDAQ:FPRX) www.equities.com - August 4 at 5:19 AM
	Commit To Purchase Five Prime Therapeutics At $35, Earn 9.7% Annualized Using Options - Nasdaq (NASDAQ:FPRX) www.nasdaq.com - August 2 at 10:40 PM